A recurrent clonally distinct Burkitt lymphoma case highlights genetic key events contributing to oncogenesis.
Adult
Alleles
Biomarkers, Tumor
Burkitt Lymphoma
/ diagnosis
Cell Transformation, Neoplastic
/ genetics
Clonal Evolution
Genetic Association Studies
/ methods
Genetic Background
Genetic Predisposition to Disease
High-Throughput Nucleotide Sequencing
Humans
Male
Models, Biological
Molecular Targeted Therapy
Mutation
Treatment Outcome
FANCM
MYC
Burkitt lymphoma
EBV
somatic mutation
whole exome sequencing
Journal
Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
14
10
2018
revised:
14
02
2019
accepted:
15
02
2019
pubmed:
20
2
2019
medline:
10
1
2020
entrez:
20
2
2019
Statut:
ppublish
Résumé
Burkitt lymphoma (BL) is characterized by a translocation of the MYC oncogene that leads to the upregulation of MYC expression, cell growth and proliferation. It is well-established that MYC translocation is not a sufficient genetic event to cause BL. Next-generation sequencing has recently provided a comprehensive analysis of the landscape of additional genetic events that contribute to BL lymphomagenesis. Refractory BL or relapsing BL are almost always incurable as a result of the selection of a highly chemoresistant clonally related cell population. Conversely, a few BL recurrence cases arising from clonally distinct tumors have been reported and were associated with a favorable outcome similar to that reported for first-line treatment. Here, we used an unusual case of recurrent but clonally distinct EBV+ BL to highlight the key genetic events that drive BL lymphomagenesis. By whole exome sequencing, we established that ID3 gene was targeted by distinct mutations in the two clonally unrelated diseases, highlighting the crucial role of this gene during lymphomagenesis. We also detected a heterozygous E1021K PIK3CD mutation, thus increasing the spectrum of somatic mutations altering the PI3K signaling pathway in BL. Interestingly, this mutation is known to be associated with activated phosphoinositide 3-kinase delta syndrome (APDS). Finally, we also identified an inherited heterozygous truncating c.5791CT FANCM mutation that may contribute to the unusual recurrence of BL.
Identifiants
pubmed: 30779244
doi: 10.1002/gcc.22743
pmc: PMC6790587
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
595-601Informations de copyright
© 2019 The Authors. Genes, Chromosomes & Cancer published by Wiley Periodicals, Inc.
Références
J Pediatr Hematol Oncol. 2014 Mar;36(2):e125-7
pubmed: 23689288
Am J Clin Pathol. 2016 Aug;146(2):248-53
pubmed: 27287777
Cancer Med. 2018 Apr;7(4):1275-1284
pubmed: 29522278
Br J Haematol. 2012 Mar;156(6):719-29
pubmed: 22482131
Genes Chromosomes Cancer. 2016 Mar;55(3):251-67
pubmed: 26608593
Clin Cancer Res. 2017 May 1;23(9):2232-2244
pubmed: 27923841
Genet Med. 2018 Apr;20(4):458-463
pubmed: 28837157
J Allergy Clin Immunol. 2017 Feb;139(2):597-606.e4
pubmed: 27555459
Br J Haematol. 2012 Mar;156(6):693-703
pubmed: 21923642
Lancet. 2016 Jun 11;387(10036):2402-11
pubmed: 27080498
Nat Genet. 2012 Dec;44(12):1316-20
pubmed: 23143595
Nat Commun. 2015 Dec 22;6:10086
pubmed: 26689913
Curr Opin Hematol. 2014 Jul;21(4):326-32
pubmed: 24867287
Blood. 1996 Aug 15;88(4):1407-10
pubmed: 8695860
Nat Genet. 2012 Dec;44(12):1321-5
pubmed: 23143597
Cancer Cell. 2012 Aug 14;22(2):167-79
pubmed: 22897848
Int J Hematol. 2015 May;101(5):520-4
pubmed: 25555480
Hum Mol Genet. 2015 Sep 15;24(18):5345-55
pubmed: 26130695
Curr Opin Genet Dev. 2015 Aug;33:32-40
pubmed: 26254775
Breast Cancer Res Treat. 2017 Nov;166(1):217-226
pubmed: 28702895
JAMA Oncol. 2017 Sep 1;3(9):1245-1248
pubmed: 28033443
Genes Chromosomes Cancer. 2019 Aug;58(8):595-601
pubmed: 30779244
Haematologica. 2009 Apr;94(4):487-95
pubmed: 19278965
Oncotarget. 2018 Apr 24;9(31):21820-21830
pubmed: 29774105
Clin Adv Hematol Oncol. 2012 Jan;10(1):54-5
pubmed: 22398809
Blood. 1988 Aug;72(2):792-5
pubmed: 3401598
Clin Cancer Res. 2016 Jun 15;22(12):2919-28
pubmed: 26819451
Front Immunol. 2018 Jun 04;9:1103
pubmed: 29942301